The UK’s National Institute for Health and Care Excellence (NICE) has not recommended the routine use of Roche’s Perjeta (pertuzumab)...
Read More...
The post NICE advises against NHS use of Roche’s Perjeta for breast cancer appeared first on Pharmaceutical Technology.
Original Article: NICE advises against NHS use of Roche’s Perjeta for breast cancer